GFP
XBI icon

Gryphon Financial Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Gryphon Financial Partners’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,400
Closed -$178K – 243
2022
Q2 		$178K Buy
2,400
+65
+3% +$4.88K 0.04% 183
2022
Q1 		$210K Buy
2,335
+50
+2% +$4.62K 0.04% 187
2021
Q4 		$256K Buy
2,285
+15
+0.7% +$1.81K 0.05% 179
2021
Q3 		$285K Sell
2,270
-270
-11% -$34.8K 0.06% 159
2021
Q2 		$344K Sell
2,540
-100
-4% -$13.1K 0.08% 133
2021
Q1 		$358K Buy
2,640
+30
+1% +$4.49K 0.08% 125
2020
Q4 		$367K Buy
2,610
+20
+0.8% +$2.56K 0.09% 111
2020
Q3 		$289K Buy
2,590
+20
+0.8% +$2.24K 0.09% 122
2020
Q2 		$288K Sell
2,570
-20
-0.8% -$1.97K 0.09% 108
2020
Q1 		$201K Buy
+2,590
New +$229K 0.07% 134
2018
Q3 		– Sell
-170
Closed -$16K – 838
2018
Q2 		$16K Hold
170
– – 0.01% 419
2018
Q1 		$15K Sell
170
-86
-34% -$7.85K 0.01% 442
2017
Q4 		$22K Buy
+256
New +$21.4K 0.01% 385

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Gryphon Financial Partners's XBI Position: Q3 2022 in Review

Gryphon Financial Partners sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2022, closing a stake of 2,400 shares — an estimated $178K sold.

Gryphon Financial Partners first reported a position in XBI in Q4 2017 and held it in 13 quarters. The position peaked at $367K in Q4 2020. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

  • Gryphon Financial Partners reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2022 after selling out during the quarter.
  • Gryphon Financial Partners sold 2,400 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $178K.
  • Gryphon Financial Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and held it in 13 quarters.
  • Gryphon Financial Partners's State Street SPDR S&P Biotech ETF position peaked at $367K in Q4 2020.
  • 704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Gryphon Financial Partners's 13F filing for Q3 2022, filed 14 Nov 2022.